FDA expands approval for childhood leukemia drug

01/27/2013 | Bloomberg Businessweek

The FDA approved Friday the expanded use of Novartis' leukemia drug Gleevec to include children newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia. The drug should be combined with chemotherapy and carries a risk of several adverse reactions, including liver toxicity and infections, the agency said.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC